Safety and Efficacy Evaluation of Decitabine With R-GDP

• Status: Unknown status
• Trial end date: 2020-11-01
• Target enrollment: 0
• Participant gender: All

Summary

Assessment of the Safety and efficacy of Administering decitabin plus R-GDP to NHL patients

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Beijing Immunochina Medical Science & Technology Co., Ltd.
• Treatments: Azacitidine; Decitabine

Criteria

Inclusion Criteria:

1. Relapsed or refractory Non-Hodgkin's lymphoma(NHL) patiens.

2. Eastern Cooperative Oncology Group(ECOG) score 0-2

3. Expected survival >3 months

4. Measurable disease.

Exclusion Criteria:

1. Patients who needs treatment with immunosuppressive agents

2. Hematosepsis or Uncontrolled active infection

3. History of epilepsy or other CNS disease.

4. Active hepatitis B , hepatitis C or HIV infection or any other uncontrolled active infection.

5. Pregnancy or breast-feeding women.

6. Any uncontrolled medical disorders that the researchers considered are not suitable to participate the clinical trial.

7. Any situation that would increase dangerousness of subjects or disturb the outcome of the clinical study according to the researcher's evaluatio